1-2 of 2
Teeru Bihani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR10: RAD1901, an orally available selective estrogen receptor downregulator, has potent anti-tumor activity in in vitro and in vivo models of ER+ breast cancer

Free
Teeru Bihani, Jeffrey Brown, Gary Hattersley, Fiona Garner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR10.
https://doi.org/10.1158/1535-7163.TARG-15-PR10
Published: 01 December 2015
View article titled, Abstract PR10: RAD1901, an orally available selective estrogen receptor downregulator, has potent anti-tumor activity in in vitro and in vivo models of ER+ breast cancer
Journal Articles

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Free
Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D'Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2508–2518.
https://doi.org/10.1158/1535-7163.MCT-15-0365
Published: 03 November 2015
View article titled, AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Open the PDF for AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules in another window
Includes: Supplementary data